<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Neo YN</dc:creator>
  <dc:creator>Panos GD</dc:creator>
  <dc:creator>Gatzioufas Z</dc:creator>
  <dc:creator>Vergados A</dc:creator>
  <dc:date>2020</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Glaucoma is one of the leading causes of visual loss in industrialized world. Local lowering intra-ocular pressure drops are the first-line treatment for glaucoma. Penetrating and nonpenetrating surgery is considered when topical lowering intra-ocular pressure drops fail. Recently, the iStent® device has been introduced in the management of glaucoma nonresponding sufficiently to local treatment. In this review, we present the results of the trials concerning the efficacy and safety of iStent for the treatment of open angle glaucoma.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/174270</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4155/tde-2020-0045</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32522140</dc:relation>
  <dc:source>Therapeutic delivery. - 2020</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">glaucoma</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">iStent®</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">surgery</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">treatment</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">Ab interno trabecular bypass surgery with iStent® and iStent inject® for open angle glaucoma.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>